Pfizer Plans to Seek FDA Nod for COVID-19 Booster Next Month as Delta Spreads
07/09/2021
Pfizer’s chief scientific officer Mikael Dolsten indicated Thursday that the company plans to seek an FDA emergency-use authorization next month for a third dose of its COVID-19 vaccine BNT162b2, according to a FirstWord report.
The mRNA-based vaccine, partnered with BioNTech, is currently authorized in the US to be administered as two doses in people as young as 12. However, the companies highlighted initial data from a booster study suggesting that a third shot, given about 6 months after the second, induces neutralization titres against the original virus and Beta variant (B.1.351) that are five to 10 times higher than after the two primary doses.